Many Alzheimer’s disease (AD) patients suffer from cerebrovascular abnormalities such as altered cerebral blood flow and cerebral microinfarcts. Recently, fibrinogen has been identified as a strong cerebrovascular risk factor in AD, as it specifically binds to β-amyloid (Aβ), thereby altering fibrin clot structure and delaying clot degradation. To determine if the Aβ–fibrinogen interaction could be targeted as a potential new treatment for AD, we designed a high-throughput screen and identified RU-505 as an effective inhibitor of the Aβ–fibrinogen interaction. RU-505 restored Aβ-induced altered fibrin clot formation and degradation in vitro and inhibited vessel occlusion in AD transgenic mice. Furthermore, long-term treatment of RU-505 significantly reduced vascular amyloid deposition and microgliosis in the cortex and improved cognitive impairment in mouse models of AD. Our studies suggest that inhibitors targeting the Aβ–fibrinogen interaction show promise as therapy for treating AD.

01 Mar 2006·The Journal of Physical Chemistry BQ3 · CHEMISTRY

Electron-Transfer Dynamics from Ru Polypyridyl Complexes to In₂O₃ Nanocrystalline Thin Films

Q3 · CHEMISTRY

Article

Author: Stockwell, David ; Anderson, Neil A. ; Guo, Jianchang ; Lian, Tianquan ; She, Chunxing ; Ai, Xin

Photoinduced electron injection dynamics from Ru(dcbpy)(2)(X)(2) (dcbpy = 4,4'-dicarboxy-2,2'-bipyridine; X(2) = 2SCN(-), 2CN(-), and dcbpy; referenced as RuN3, Ru505, and Ru470) to In(2)O(3) nanocrystalline thin films were studied using ultrafast transient IR absorption spectroscopy. After 532 nm excitation of the adsorbates, the dynamics of electron injection from their excited states to In(2)O(3) were studied by monitoring the IR absorption of the injected electrons in the semiconductor. The injection kinetics were non-single-exponential. For samples exposed to air, the half rise times, defined as the time of 50% injection yield, were 5 +/- 0.8, 85 +/- 20, and >200 ps for RuN3, Ru505, and Ru470, respectively. For samples in pH 2 buffer, the corresponding half time for injection from these complexes became 6 +/- 1, 105 +/- 20, and 18 +/- 5 ps. The injection kinetics from RuN3 to In(2)O(3) was found to be similar to that to SnO(2). These kinetics traces showed a negligible <100 fs injection component and were very different from those to TiO(2). The dependences of the injection kinetics on adsorbate energetics and the nature of the semiconductors are discussed.

01 Apr 2005·The Journal of Physical Chemistry BQ3 · CHEMISTRY

Electron Injection Dynamics of Ru Polypyridyl Complexes on SnO₂ Nanocrystalline Thin Films

Q3 · CHEMISTRY

Article

Author: Guo, Jianchang ; Ai, Xin ; Lian, Tianquan ; Anderson, Neil A.

Ultrafast infrared spectroscopy was utilized to investigate the electron-transfer dynamics from Ru(dcbpy)(2)(X)(2) complexes (dcbpy = 4,4'-dicarboxy-2,2'-bipyridine; X(2) = SCN(-), 2CN(-), and dcbpy; referenced as RuN3, Ru505, and Ru470, respectively) to nanocrystalline SnO(2) films. For both films exposed to air (dry) and submerged in a pH 2 buffer solution, all traces show biphasic dynamics with a small ultrafast component (less than 10%) and nonexponential slow component, indicating that most injection occurs from thermalized excited state of the dye. In the dry film, the injection rate becomes slower, comparing RuN3, Ru505, and Ru470, correlating with decreasing excited-state oxidation potentials in these dyes. However, the variation of injection rate with dye potential is less noticeable at pH 2. The possible reason for the different injection dynamics in these dyes and under different environments are discussed. These injection dynamics are also compared with those on TiO(2) and ZnO.

100 Deals associated with RU-505

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Preclinical	US	The Rockefeller University	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

RU-505

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation